Clinical trials: Streamline or Workflow, Resulting in Reduced or Time
- Condition Streamline or Workflow, Resulting in Reduced or Time
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Attention-Deficit/Hyperactivity Disorder
Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate
This study will evaluate how long it takes for ADHD symptoms to improve in subjects who are judged by the Investigator to have had an inadequate response to methylphenidate therapy.
- Trial name
- NCT01106430
- Testing
- Lisdexamfetamine Dimesylate, Atomoxetine Hydrochloride
- Where
- 64 sites in United States, Belgium and 8 more
- Volunteers
- 267 people
- Sponsor
- Shire
Migraine
A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers
This is a single-center, open-label, randomized, four-way crossover study. Each subject will receive each of the four study treatments once, followed by in-clinic monitoring and extensive blood sample collection for…
- Trial name
- NCT03708744
- Testing
- A: M207 3.8mg, 30 min, upper arm, B: M207 3.8 mg, 30 min, thigh, C: M207 3.8 mg, 1 hr, upper arm
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Zosano Pharma Corporation
Chronic Lymphocytic Leukemia (CLL)
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
The purpose of this open-label, single-arm study was to evaluate the impact of venetoclax on the quality of life of participants including those with with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL; a type of…
- Trial name
- VENICE II (NCT02980731)
- Testing
- Venetoclax
- Where
- 33 sites in Argentina, Australia and 8 more
- Volunteers
- 210 people
- Sponsor
- AbbVie
Carcinoma, Non-Small-Cell Lung
Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population
This trial is an extension to ENSURE, a study of erlotinib versus gemcitabine/cisplatin combination chemotherapy as the first-line treatment for patients with non-small-cell lung cancer (NSCLC) with mutations in the tyrosine…
- Trial name
- NCT02000531
- Testing
- Erlotinib, Chemotherapy
- Where
- 11 sites in China
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Healthy
Duration of Effect of Acidform Gel on Vaginal pH
The objective of this study was to determine the magnitude and duration of the reduction in pH (acidification) following a single dose of Acidform vaginal gel containing 3, 4, or 5 g compared with hydroxyethylcellulose placebo…
- Trial name
- NCT02693418
- Testing
- Acidform 5 g, Acidform 4 g, Acidform 3 g
- Where
- 2 sites in United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Evofem Inc.
Stomatitis, Oral Mucositis
Efficacy of SNX-1012 in the Treatment of Oral Mucositis
Oral mucositis (OM) is a common and debilitating toxicity induced by many chemotherapy (CT) regimens and by radiation to the head and neck.
- Trial name
- NCT00385515
- Testing
- SNX-1012 (meclocycline sulfosalicylate)
- Where
- 27 sites in United States, India
- Volunteers
- 81 people
- Sponsor
- Mucosal Therapeutics
Dyslipidemia, Hyperlipidemia
Rosuvastatin Adherence App Study in China
This is a randomized, two-arm, open label, Phase IV clinical trial to evaluate if the provision of a smart phone-based patient support tool prolongs the patient's rosuvastatin treatment duration.
- Trial name
- eHELP China (NCT02433288)
- Testing
- Smart phone based patient support tool, Control application: only for data collection
- Where
- 25 sites in China
- Volunteers
- 885 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
Primary Objective: To compare lixisenatide versus insulin glulisine in terms of glycosylated hemoglobin (HbA1c) reduction and body weight change at Week 26 in type 2 diabetic participants not adequately controlled on insulin…
- Trial name
- GetGoal-Duo-2 (NCT01768559)
- Testing
- Lixisenatide (AVE0010), Insulin glulisine QD, Insulin glulisine TID
- Where
- 199 sites in United States, Canada and 16 more
- Volunteers
- 894 people
- Sponsor
- Sanofi
Prostatic Neoplasms
A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
The purpose of this study is to learn about how long novel hormonal therapies are taken by men to treat mCSPC. Novel hormonal therapies in this study include study medicines abiraterone, apalutamide, and enzalutamide.
- Trial name
- NCT06072196
- Testing
- Novel hormonal therapy
- Where
- United States
- Volunteers
- 3,017 people
- Sponsor
- Pfizer
Locally Advanced or Metastatic Medullary Thyroid Cancer, Medullary Thyroid Cancer
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
The purpose of this study is to evaluate the effect of patient outreach program on the proportion of time patients with MTC experience moderate or severe AEs during first 12 months of treatment with vandetanib
- Trial name
- NCT01298323
- Testing
- Patient outreach, Vandetanib
- Where
- 66 sites in Australia, Austria and 18 more
- Volunteers
- 205 people
- Sponsor
- Sanofi
Refractive Error
Tear Film Evaluation of Dailies® AquaComfort Plus® Multifocal and Toric
The purpose of this study is to evaluate the pre lens tear film characteristics of DAILIES® Aqua Comfort Plus® Multifocal (DACP MF) and Toric (DACP Toric) compared to DAILIES® Aqua Comfort Plus® Sphere (DACP) daily disposable…
- Trial name
- NCT02289742
- Testing
- Nelfilcon A multifocal contact lenses, Nelfilcon A toric contact lenses, Nelfilcon A sphere contact lenses
- Volunteers
- 48 people
- Sponsor
- Alcon Research
Hypertension
A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)
The purpose of this study was to evaluate the magnitude and durations of the antihypertensive effects of losartan using ambulatory blood pressure monitoring (ABPM), and to evaluate the safety of losartan 50 and 100 mg doses…
- Trial name
- NCT00886600
- Testing
- losartan potassium, hydrochlorothiazide (HCTZ)
- Volunteers
- 122 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Sclerosis
A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study
The purpose of this study is to test the RebiSmart™ for ease of use multiple domains related to subject's acceptability and satisfaction reliability of the correct function for self-injection of Rebif® 44 mcg sc tiw in subjects…
- Trial name
- Performs (NCT01036165)
- Testing
- RebiSmart™
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- EMD Serono
Type 1 Diabetes Mellitus
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
The primary purpose of participation in this study is to compare the safety and efficacy of different dosing schedules of LY2605541 and how different dosing schedules of LY2605541 affect Hemoglobin A1c (HbA1c).
- Trial name
- IMAGINE 7 (NCT01792284)
- Testing
- LY2605541, Insulin Lispro
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 212 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis, Relapsing-Remitting
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
The purpose of this study was to establish the efficacy and safety of two different doses of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous interferon…
- Trial name
- CARE-MS II (NCT00548405)
- Testing
- Alemtuzumab 12 mg, Alemtuzumab 24 mg, Interferon beta-1a
- Where
- 191 sites in United States, Argentina and 21 more
- Volunteers
- 840 people
- Sponsor
- Genzyme, a Sanofi Company
Male Hypogonadism, Primary Hypogonadism
Pharmacokinetic Study to Determine Time to Steady-state
The purpose of the study is to confirm how long (i.e., how many days) it takes to reach steady-state when testosterone undecanoate is administered twice daily.
- Conditions
- Male Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism
- Trial name
- NCT00911586
- Testing
- Testosterone undecanoate
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Clarus Therapeutics, Inc.
Idiopathic Pulmonary Fibrosis
Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
The main objectives of this study are: Determine the difference in change from baseline in Six Minute Walk Distance (6MWD) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with…
- Trial name
- NCT03717012
- Testing
- Nintedanib, Pulmonary rehabilitation program
- Where
- 19 sites in United States
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.
This is a randomised, double-blind, double-dummy, multinational, multicentre, parallel group trial comparing tiotropium (18 mcg) inhalation capsule via HandiHaler and salmeterol (50 mcg) via MDI in patients with COPD.
- Trial name
- NCT00563381
- Testing
- Tiotropium bromide, Salmeterol
- Where
- 752 sites in Austria, Belgium and 23 more
- Volunteers
- 7,376 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Basal Cell
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
This study is to determine the recommended phase II dose (RP2D) and schedule of CX-4945 when administered orally twice daily for 28 consecutive days, in a 4-week (28 days) cycle, in patients with locally advanced or metastatic…
- Trial name
- NCT03897036
- Testing
- CX-4945
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Senhwa Biosciences, Inc.
Frown Lines
Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines
The purpose of the study is to provide preliminary comparative data on BoNT/A-DP versus Botox Cosmetic. Subsequently the sample size is primarily based on clinical judgement and practical considerations.
- Trial name
- H2H (NCT04763265)
- Testing
- Botulinum toxin A "BoNT/A-DP", Botulinum toxin A "Botox Cosmetics"
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 208 people
- Sponsor
- Croma-Pharma GmbH